Skip to main content
Hester Biosciences Ltd logo

Hester Biosciences Ltd — Investor Relations & Filings

Ticker · HESTERBIO ISIN · INE782E01017 LEI · 984500836B9EB1DC4935 BSE.NS Manufacturing
Open in API
Filings indexed 672 across all filing types
Latest filing 2020-02-29 Regulatory Filings
Country IN India
Listing BSE.NS HESTERBIO

About Hester Biosciences Ltd

https://www.hester.in/

Hester Biosciences Ltd specializes in the development, manufacturing, and marketing of animal healthcare products. The company primarily focuses on two segments: poultry healthcare and livestock healthcare. Its extensive product portfolio includes a wide range of live and inactivated vaccines, as well as health products such as therapeutics, herbal supplements, and disinfectants. Hester is recognized for its significant contributions to global animal disease control programs, particularly in the eradication of Peste des Petits Ruminants (PPR) and Brucellosis. The company operates advanced manufacturing facilities and maintains a robust distribution network to serve domestic and international markets. By leveraging research and development, Hester provides diagnostic services and technical support to enhance animal productivity and welfare. Its commitment to quality and innovation has established it as a key provider of biologicals and health solutions for the veterinary sector.

Recent filings

Filing Released Lang Actions
Board Meeting — Other business matters
Regulatory Filings
2020-02-29 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of an earnings conference call held by Hester Biosciences Limited on 7 February 2020, discussing the financial results for the quarter and nine months ended 31 December 2019. It includes detailed management commentary on financial performance, business outlook, and Q&A with analysts. The presence of a full transcript of the call, including moderator and participant dialogue, confirms this is a Call Transcript (CT). The document length (15,000 characters) and content confirm it is not a brief announcement or summary but a full transcript. Therefore, the appropriate classification is Call Transcript (CT).
2020-02-10 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated 7 February 2020, providing detailed financial highlights and business overviews for Q3FY20 and 9MFY20 periods. It includes sales, profit, EPS, margin analysis, and segment-wise revenue contributions. The document discusses operational updates, market conditions, and strategic collaborations. It contains substantive financial data and analysis for interim periods (quarter and nine months), not just a brief announcement or summary. There is no indication that this is a full annual report or just an announcement of a report. The content aligns with an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year with detailed financial statements and business commentary.
2020-02-07 English
Financial Result Updates
Regulatory Filings
2020-02-07 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 100% confidence The document is dated 7 February 2020 and addressed to stock exchanges (BSE and NSE) with a subject indicating the outcome of a Board Meeting and submission of Standalone and Consolidated Unaudited Financial Results for the quarter and nine months ended 31 December 2019. It references SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and includes detailed financial data for the quarter and nine months ended 31 December 2019, including revenue, expenses, profit before tax, tax expense, and earnings per share. The document also mentions a Limited Review Report attached, which is typical for quarterly or interim financial results. The presence of unaudited financial results for a period shorter than a full fiscal year (quarter and nine months) with substantive financial data and analysis confirms this is an Interim / Quarterly Report. It is not an announcement of a report publication but contains actual financial data, so it is not an RPA or RNS. Therefore, the correct classification is Interim / Quarterly Report (IR).
2020-02-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is a notification addressed to stock exchanges about an upcoming earnings conference call scheduled for 7 February 2020. It references the discussion of unaudited financial results for the quarter and nine months ended 31 December 2019. The document contains no actual financial data or detailed financial statements but serves to inform about the call where such results will be discussed. This matches the definition of a Call Transcript (CT) announcement, specifically the intimation of an earnings conference call. The document length is short and it is an announcement rather than the transcript itself, but since the content is about the earnings call, the best fitting category is Call Transcript (CT).
2020-02-03 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.